ISACA Provides Guidance Around EU’s Proposed Digital Operational Resilience Act
14.10.2021 17:19:00 EEST | Business Wire | Press release
Reforms following the 2008 financial crisis helped strengthen the resilience of the financial sector, but did not fully address digital operational resilience. The European Union’s recently released Digital Operational Resilience Act (DORA) draft is designed to provide digital operational resilience rules for EU financial institutions, and ISACA provides guidance on this proposal in its new white paper, Digital Operational Resilience in the EU Financial Sector: A Risk-Based Approach .
When finalized, DORA will enact rules for financial services system operators like investment firms, credit institutions, trading venues and electronic money institutions to ensure these systems’ stability and resilience to cyber incidents. Digital Operational Resilience in the EU Financial Sector outlines the objectives and legal basis for DORA, as well as its information and communication technology (ICT) requirements around risk management, information and cybersecurity, incident reporting, testing, and oversight of third-party service providers, some of which include:
- Set up and maintain resilient ICT systems and tools that minimize the impact of ICT risk.
- Have an ICT risk-management framework that includes strategies, policies, procedures, ICT protocols and tools necessary to effectively protect all relevant physical components and infrastructures from risk, such as damage and unauthorized access or usage.
- Test the ICT business continuity policy and the ICT disaster recovery plan at least yearly, and after substantive changes to the ICT systems.
- Include relevant provisions on accessibility, availability, integrity, security and protection of personal data, and guarantees for access, recover and return in the case of failures of the ICT third-party service providers in contracts that govern the relationship with third-party providers.
“The requirements laid out in DORA to identify all sources of ICT risk on a continuous basis and mandate an annual review of ICT risk management frameworks and review after a major incident, audit or testing are a step in the right direction,” says Chris Dimitriadis, ISACA chief global strategy officer. “However, to further strengthen the act, ISACA encourages provisions ensuring that ICT risk management plans go beyond being a compliance exercise by embedding governance responsibility within the management body, as well as requiring continuous training and ICT awareness of senior management and staff and independent testing performed by testers who are certified.”
During this period in which the DORA regulation is under consideration in the European Parliament and Council of the EU, ISACA’s EU Task Force is engaging with policy makers and sharing feedback. The final version of the regulation is expected in an estimated 18-24 months.
“ISACA is recognized among policy makers as an independent source of expertise on cybersecurity issues. The variety of backgrounds and experience of our members, reflected in the EU Task Force, have been welcomed by policy makers who have valued our contributions to the debate,” says Emily Bastedo, ISACA director for global government relations and public affairs.
To download a complimentary copy of Digital Operational Resilience in the EU Financial Sector, visit https://store.isaca.org/s/store#/store/browse/detail/a2S4w000004L1sxEAC. Additional publications that may be helpful for financial entities as they prepare for DORA include ISACA’s Risk IT Framework, 2nd Edition; Risk IT Practitioner Guide, 2nd Edition ; and IT Risk Fundamentals Study Guide. Other IT risk-related resources can be found at www.isaca.org/resources/it-risk.
About ISACA
For more than 50 years, ISACA® (www.isaca.org) has advanced the best talent, expertise and learning in technology. ISACA equips individuals with knowledge, credentials, education and community to progress their careers and transform their organizations, and enables enterprises to train and build quality teams. ISACA is a global professional association and learning organization that leverages the expertise of its more than 150,000 members who work in information security, governance, assurance, risk and privacy to drive innovation through technology. It has a presence in 188 countries, including more than 220 chapters worldwide. In 2020, ISACA launched One In Tech, a philanthropic foundation that supports IT education and career pathways for under-resourced, under-represented populations.
Twitter:
www.twitter.com/ISACANews
LinkedIn:
www.linkedin.com/company/isaca
Facebook:
www.facebook.com/ISACAGlobal
Instagram:
www.instagram.com/isacanews
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211014005760/en/
Contact information
Emily Van Camp, evcamp@isaca.org, +1.847.385.7223
Kristen Kessinger, communications@isaca.org, +1.847.660.5512
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
